To achieve these objectives, the partners will unite their scientific teams and pool their expertise and know-how to transform innovative projects into programs ready for industrial development. As ...

France's Ose Immunotherapeutics will enrol up to 400 patients for the first two stages of clinical trials of an experimental coronavirus vaccine it hopes will provide an extra weapon in battle against ...

BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second ...

OSE Immunotherapeutics’s Phase II trial examining its neoepitope-based therapeutic cancer vaccine Tedopi (OSE2101) in patients with pancreatic ductal adenocarcinoma (PDAC) has impacted one-year ...

A total of 105 HLA-A2 positive patients enrolled in the Combi-TED study, which explores the combination of Tedopi® with either an anti-PD1 checkpoint inhibitor or chemotherapy as a second-line ...

NSF said the initial cohort will address critical vulnerabilities in open-source software and its deployment pipelines.

OSE Immunotherapeutics (OTC:ORPOF) has announced a leadership transition following a decision by its board of directors. The ...

Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30 th General Meeting ...

At the ISC High Performance 2025 event hosted in Hamburg, Germany, speakers discussed how innovation in HPC and AI technology is driving new innovation that aims to keep pace with Moore's Law as ...